Trials / Active Not Recruiting
Active Not RecruitingNCT06438757
Trial of JYB1904 in Patients With Allergic Asthma
Phase IIa Trial to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety of JYB1904 in Patients With Allergic Asthma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Jemincare · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JYB1904 | Participants will receive JYB1904 every 8 weeks for 24 weeks. |
| DRUG | Omalizumab | Participants will receive Omalizumab every 2/4 weeks for 24 weeks. |
Timeline
- Start date
- 2024-06-19
- Primary completion
- 2025-10-31
- Completion
- 2025-10-31
- First posted
- 2024-06-03
- Last updated
- 2025-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06438757. Inclusion in this directory is not an endorsement.